ClinicalTrials.gg
CompletedNCT03891238ARIESUpdated Feb 1, 2024

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

A Phase 2 interventional study of Avelumab in Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer, sponsored by Consorzio Oncotech. Completed at 21 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by Consorzio Oncotech · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing avelumab in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. avelumab · Neoplasm Metastasis.

Enrollment
5th of 10
67 · median 46
Started
2019
with 1 other
Phase 2
6 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Consorzio Oncotech

Among the 10 studies testing avelumab in Neoplasm Metastasis, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 2, and was the 7th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 10 studies testing avelumab in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing avelumab in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This is a single arm, open label, phase II study to evaluate the activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced urothelial cancer considered unfit to cisplatin-based chemotherapy, to be conducted in conformance with Good Clinical Practices.

Cisplatin-unfit patients will be defined if at least one of these characteristics is present:

  1. ECOG-Performance status = 2;
  2. Creatinine Clearance \< 60 ml/min;
  3. Grade 2 or worse peripheral neuropathy or hearing loss;
  4. Previous treatment with cisplatin for adjuvant intent in six months before the progression of disease.
Read the detailed description

Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of 28 days, each subject will receive the treatment. Treatment on trial will continue until disease progression is confirmed by the investigator/site radiologist, unacceptable adverse event(s), intercurrent illness that prevents further administration of treatment, investigator's decision to withdraw the subject, subject withdrawals consent, pregnancy of the subject, noncompliance with trial treatment or procedures requirements, or administrative reasons.

The study treatment may be continued after radiological progression of disease at physician discretion and if improvement of symptoms or not new symptoms were reported by the patient despite the radiological progression of disease.

Subjects who attain a complete response may consider stopping trial treatment if they meet criteria for holding therapy.

After the end of treatment given the potential risk for delayed immune-related toxicities, safety follow-up must be performed up to 90 days after the last dose of avelumab administration.

The extended safety follow-up beyond 30 days after last study drug administration may be performed either via a site visit or via a telephone call with subsequent site visit requested in case any concerns noted during the telephone call.

Subjects who discontinue for reasons other than disease progression will have post-treatment follow-up every 12 weeks for disease status until disease progression is confirmed by the investigator/site radiologist, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed by telephone for overall survival every 12 weeks until death, withdrawal of consent, or the end of the trial.

03

Conditions studied

  • Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Browse trials for

Keywords

  • unfit for cisplatin
  • PD-L1
  • urotelian metastatic cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Be able to understand and be willing to sign a written for the trial. Informed consent obtained before any study-specific procedures.

      • Be Male or female patient ≥18 years of age on day of signing informed consent.
      • Have histologicallly or -confirmed diagnosis of urothelial cancer of the renal pelvis, ureter, bladder, or urethra. Both transitional cell and mixed transitional/non-transitional cell histologies are allowed, but transitional cell carcinoma must be the predominant histology. Subjects with non-urothelial cancer of the urinary tract are not allowed.
      • Have measurable or non- according to criteria (RECIST), version 1.1.
      • Have immunohistochemical expression of ≥ 5% on tumor cells in archived tumor .
      • Have a performance status of ≤2 on the (ECOG) Performance Scale, as assessed within 10 days prior to treatment initiation.
      • Have a of at least 6 months.
      • Female subject of and men must agree to use adequate since signing of the informed consent form until at least 3 months after the last study drug administration. The investigator or a designated associate is requested to advise the subject how to achieve an adequate birth control. Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last avelumab treatment administration if the risk of conception exists. Adequate contraception is defined in the study as any medically recommend method (or combination of methods) as per standard of care.
      • Respect the Cisplatin-unfit criteria, defined if at least one of these characteristics is present:
    1. ECOG-Performance status = 2;
  • \< 60 ml/min;
  • Grade 2 or worse peripheral neuropathy or hearing loss;
  • Previous treatment with cisplatin for adjuvant intent in six months before the progression of disease.

    • Demonstrate adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:
  • (ANC) ≥ 1.5 × 109/L, count ≥ 100 × 109/L, and ≥ 9 g/dL (may have been transfused);
  • Total ≤1∙5 × the (ULN); or Direct bilirubin \< ULN for subjects with total bilirubin levels >1.5xULN;
  • (ALT) and aspartate aminotransferase (AST), levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented disease to the liver);
  • (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care;
  • Platelet count ≥100.000/mm3, hemoglobin >9 g/dl, absolute neutrophil count >1.500/mm3;
  • Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver metastases).
  • Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method);
  • Pregnancy test: negative serum or urine pregnancy test at screening for women of childbearing potential.

Exclusion criteria

Exclusion Criteria:

    • Has disease that is suitable for local therapy administered with curative intent.

      • Has received prior treatment with avelumab.
      • Has received prior therapy with an or anti-PD-L1 agent, or with an agent directed to another co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137).
      • Known prior severe to product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies ( v 5.0 Grade ≥ 3).
      • Has received previous treatment for or locally advanced urothelial cancer.
      • Has a known previous or concurrent that is progressing or requires active treatment and is distinct in primary site or histology from urothelial cancer within 5 years before randomization.

Exceptions cervical cancer in situ or basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy. A history of prostate cancer that was identified incidentally following cystoprostatectomy for bladder cancer is acceptable, provided that the following criteria are met:

  • Stage T2N0M0 or lower;
  • Gleason score ≤ 6,
  • PSA undetectable.

    • Has major surgical procedure, open , or significant traumatic injury within 28 days before start of study medication
    • Has active cardiac disease, defined as:

      1. Myocardial infarction or unstable angina pectoris within 6 months of the first date of study therapy.
      2. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of prolongation.
      3. (NYHA) Class III or greater congestive heart failure, or of \< 40%.
    • Has uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
    • Has arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), pulmonary embolism within the 4 months before start of study medication.
    • Persisting toxicity related to prior therapy (NCI CTCAE v. 5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable
    • Active infection higher than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 grade 2 requiring systemic therapy.
    • Known history of testing positive for or known acquired immunodeficiency syndrome.
    • virus (HBV) or virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
    • Has seizure disorder requiring medication.
    • Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
    • Has known symptomatic metastatic central nervous system (CNS) and/or meningeal tumors. Subjects with previously treated may partecipate provided they are stable (the patient is >2 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable - any neurologic symptoms have returned to baseline - with respect to the tumor at the time of study entry). Also, the patient must not be undergoing acute therapy or tapering (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before and after screening radiographic studies). This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.
    • Has a history of organ allograft.
    • Has evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication.
    • Has non-healing wound, ulcer, or bone fracture.
    • Has renal failure requiring hemodialysis or peritoneal dialysis.
    • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
    • Active disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
    • Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
    • Dehydration of NCI-CTCAE version 5.0 grade 1 or higher.Prior organ transplantation including allogenic stem-cell transplantation.
    • Non-healing wound, ulcer, or bone fracture.
    • Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
    • Has a history of substance abuse or medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
    • Has illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study.
    • Has interstitial lung disease with ongoing signs and symptoms at the time of .
    • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Avelumab Arm

    Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).

    Drug: Avelumab

Interventions

  • Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).

06

What researchers measure

Primary outcomes

  1. Efficacy Endpoints

    This study aims to evaluate the anti-tumor efficacy of avelumab in patients with metastatic or locally advanced PD-L1 positive urothelial cancer not eligible for cisplatin-based chemotherapy. Overall Survival (OS) is the best endpoint to demonstrate the efficacy of antineoplastic immunotherapy. OS is defined as the time from study entry to the date of death (whatever the cause). The survival time of living patients will be censored at last date on which the patient is known to be alive or lost to follow-up. Subject status will be followed every 2 weeks while on treatment and then every 3 months thereafter.

    Time frame: 2years

Secondary outcomes

  1. Median Progression-Free Survival (mPFS)

    • mPFS: calculated from the date of study entry (first administration of avelumab) to date of documented radiographic progression or death according to RECIST Version 1.1 criteria. The primary analyses of PFS will be based on investigator's assessments using RECIST 1.1 criteria.

    Time frame: 18 months

  2. Objective response rate (ORR)

    • ORR: defined as complete response (CR) or partial response (PR) according to RECIST Version 1.1 criteria as determined by investigator's assessments, obtained from start of study drug until documented radiographic disease progression. The first on study radiographic imaging assessment will be performed at 8 weeks (± 7 days) after first dose of study treatment and then every 12 weeks (± 7 days) thereafter or more frequently if clinically indicated. PR are those with greater than or equal to 30 percent decrease in the sum of the products of diameters (SOPD) of index lesions compared to the baseline SOPD, with no evidence of progressive disease (PD).

    Time frame: 18 months

  3. Safety Endpoints

    The primary safety analysis will be based on subjects who experienced toxicities as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 criteria. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received avelumab, including serious adverse events (SAEs) and events of clinical interest (ECIs). Safety will be assessed by reported adverse events (AEs) according to NCI CTCAE version 5.0.

    Time frame: 2 years

  4. Patient Reported Outcomes (PRO)

    The study aims to evaluate the quality of life assessed by EuroQoL EQ-5D. The eEuroQol-5D (eEQ-5D) is a standardized instrument for use as a measure of health outcome. The eEQ-5D will provide data for use in economic models and analyses including developing health utilities or QALYs. The five health state dimensions in this instrument include the following: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a three-point scale from 1 (extreme problem) to 3 (no problem). The eEQ-5D also includes a graded (0 to 100) vertical visual analog scale on which the patient rates his or her general state of health at the time of the assessment. The eEQ-5D is to be completed at various time points as specified in the study Flow Chart, beginning with Cycle 1 until 30 days post-treatment discontinuation.

    Time frame: 2 years

Other outcomes

  1. Exploratory Objective(s)

    Exploratory analysis will evaluate the predictive/prognostic role of the immunohistochemical expression of PD1/PD-L1 in tumor tissue samples of subjects with recurrent/progressive metastatic urothelial cancer not eligible for cisplatin-based chemotherapy and treated with avelumab.

    Time frame: 2 years

07

Study locations

21 sites
  • Istituto Tumori "Giovanni Paolo II" IRCCS Ospedale Oncologico di Bari
    Bari, 70124, Italy
  • ASST Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Ospedale Santa Croce - A.O. Ospedali Riuniti Marche Nord
    Fano, 60132, Italy
  • IRCCS Ospedale Policlinico San Martino
    Genova, 16132, Italy
  • Ospedale di Macerata - ASUR - Area Vasta N°3
    Macerata, 62100, Italy
  • Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • INT- IRCCS - Foundation G. Pascale
    Napoli, 80131, Italy
  • AOU San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Azienda Ospedaliera Universitaria di Parma
    Parma, 43126, Italy
  • Fondazione Salvatore Maugeri
    Pavia, 27100, Italy
  • A.O. Ospedali Riuniti Marche Nord
    Pesaro, 61121, Italy
  • Azienda Ospedalieo-Universitaria Pisana
    Pisa, 56126, Italy
  • Arcispedale Santa Maria Nuova Di Reggio Emilia
    Reggio Emilia, 42123, Italy
  • Policlinico Universitario Campus Bio Medico
    Roma, 00128, Italy
  • Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, 00168, Italy
  • Ospedale "S. Vincenzo" di Taormina
    Taormina, 98039, Italy
  • Azienda Ospedaliera Santa Maria
    Terni, 05100, Italy
  • Presidio Ospedaliero "Santa Maria Della Misericordia" Di Udine Sede Di Udine
    Udine, 33010, Italy
  • Az.Osp.Universitaria Integrata Verona- Borgo Trento
    Verona, 37126, Italy
  • ULSS 8 Berica- Ospedale San Bortolo di Vicenza
    Vicenza, 36100, Italy
08

References and documents

Publications

  • Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996 May;8(5):765-72. doi: 10.1093/intimm/8.5.765. PubMed 8671665 ↗
  • Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 Nov;11(11):3887-95. doi: 10.1002/j.1460-2075.1992.tb05481.x. PubMed 1396582 ↗
  • Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 1;64(3):1140-5. doi: 10.1158/0008-5472.can-03-3259. PubMed 14871849 ↗
  • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793-800. doi: 10.1038/nm730. Epub 2002 Jun 24. Erratum In: Nat Med 2002 Sep;8(9):1039. PubMed 12091876 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2021, 31 months.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's 31 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 26, 2019
StartActual
Feb 6, 2019
Primary completionActual
Sep 15, 2021
CompletionActual
Sep 15, 2021
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03891238
Lead sponsor
Consorzio Oncotech
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Feb 6, 2019
Primary completion
Sep 15, 2021
Completion
Sep 15, 2021
Last update
Feb 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avelumab

Start the discussion